Let’s make that $1B-plus: Abingworth gathers more cash, this time for its late-stage poker game. And we learned that even a biotech nuclear winter has its advantages
Talking with Kurt von Emster is always interesting. The joint managing partner has been tracking all the financial and development trends that influence his business at the global player Abingworth for years. He’s frank about the lessons — without divulging any secrets, of course — and you can learn things from him about therapeutic programs, defining true success and overall risk in dealmaking, that can otherwise be hard to suss out.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.